Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
July 2014

Recent Stories of Interest

From Specialty Pharmacy News - The country’s largest independent specialty pharmacy is going public. Diplomat Pharmacy, Inc., which has been operating since the 1970s, filed a Form S-1 with the Securities and Exchange Commission (SEC) on July 2 to raise up to $100 million in an initial public offering (IPO) of its common stock, the company disclosed July 3. It also is shoring up its specialty infusion business and expanding its presence through the recent purchase of MedPro Rx, Inc., a transaction it revealed in the filing (see story, p. 8). Read more

Consumer advocacy groups in California and Florida have taken various actions against… Read more

The FDA continued to add to its series of biosimilar documents with… Read more

Although the last of the patents on Teva Pharmaceutical Industries Ltd.’s multiple… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

July 24, 2014
FDA Accepts Sandoz’s Biosimilar Filgrastim Application

Sandoz says FDA has accepted its application for biosimilar filgrastim; company is first to file a biologic application under the biosimilar pathway

July 23, 2014
FDA OK’s Gilead’s Zydelig

FDA approves Gilead’s Zydelig for three blood cancers

July 18, 2014
Shire Agrees to Acquisition by AbbVie

On fifth attempt, Shire finally agrees to be purchased by AbbVie; deal is worth nearly $55 billion and is expected to close in the fourth quarter. Shire will move corporate tax headquarters to Britain

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?